{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:31Z","timestamp":1787070931081,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      We conducted an open-label, single-arm, multi-center phase II trial to evaluate the efficacy and safety of imatinib chemotherapy-refractory or metastatic solid tumor patients with\n                      <jats:italic toggle=\"yes\">c-KIT<\/jats:italic>\n                      mutations and\/or amplification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">c-KIT<\/jats:italic>\n                      mutations and amplification were detected using NGS. Imatinib (400 mg daily) was administered continuously in 28-day cycles until disease progression, unacceptable adverse events, or death by any cause. The primary endpoint was the objective response rate (ORR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>In total, 18 patients were enrolled on this trial. The most common tumor type was melanoma (n = 15, 83.3%), followed by ovarian cancer, breast cancer, and metastasis of unknown origin (MUO) (each n = 1, 5.5%). The total number of evaluable patients was 17, of which one patient had a complete response, six patients had partial response, and two patients had stable disease. The overall response rate (ORR) of 41.2% (95% CI 17.80\u201364.60) and a disease control rate of 52.9% (95% CI 29.17\u201376.63). The median progression-free survival was 2.2 months (95% CI 1.29\u20133.20), and median overall survival was 9.1 months (95% CI 2.10\u201316.11). The most common adverse events were edema (31.3%), anorexia (25.0%), nausea (18.8%), and skin rash (18.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Imatinib demonstrated modest anti-tumor activity and a manageable safety profile in chemotherapy-refractory solid tumors with\n                      <jats:italic toggle=\"yes\">c-KIT<\/jats:italic>\n                      mutation, especially in melanoma patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2698_22","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:53:43Z","timestamp":1719510823000},"page":"972-978","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial)"],"prefix":"10.4103","volume":"20","author":[{"given":"Hye Ryeon","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"},{"name":"Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Sun","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Ajou University Medical Center, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Joo","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1242\/dev.122.4.1291","article-title":"A cell- and developmental stage-specific promoter drives the expression of a truncated c-kit protein during mouse spermatid elongation","volume":"122","author":"Albanesi","year":"1996","journal-title":"Development"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0002-9440(10)63212-9","article-title":"Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer","volume":"164","author":"Paronetto","year":"2004","journal-title":"Am J Pathol"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT:Link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/DDDT.S89114","article-title":"Receptor tyrosine kinase (c-Kit) inhibitors:A potential therapeutic target in cancer cells","volume":"10","author":"Abbaspour Babaei","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program:The MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.tranon.2019.07.017","article-title":"Cancer panel assay for precision oncology clinic:Results from a 1-year study","volume":"12","author":"Kwon","year":"2019","journal-title":"Transl Oncol"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1634\/theoncologist.2017-0020","article-title":"Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials","volume":"22","author":"Kim","year":"2017","journal-title":"Oncologist"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40291-020-00462-x","article-title":"Use of an integrated pan-cancer oncology enrichment next-generation sequencing assay to measure tumour mutational burden and detect clinically actionable variants","volume":"24","author":"Pestinger","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ceb.2009.02.001","article-title":"Linking somatic genetic alterations in cancer to therapeutics","volume":"21","author":"Stuart","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":"Correlation between KIT expression and KIT mutation in melanoma:A study of 173 cases with emphasis on the acral-lentiginous\/mucosal type","volume":"22","author":"Torres-Cabala","year":"2009","journal-title":"Mod Pathol"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0959-8049(03)00026-1","article-title":"Lack of c-kit exon 11 activating mutations in c-KIT\/CD117-positive SCLC tumour specimens","volume":"39","author":"Burger","year":"2003","journal-title":"Eur J Cancer"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2005.02.093","article-title":"KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors","volume":"23","author":"Sihto","year":"2005","journal-title":"J Clin Oncol"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(00)00387-6","article-title":"Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma","volume":"154","author":"Jeng","year":"2000","journal-title":"Cancer Lett"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjc.6604482","article-title":"Phase II trial of imatinib mesylate in patients with metastatic melanoma","volume":"99","author":"Kim","year":"2008","journal-title":"Br J Cancer"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/cncr.21834","article-title":"Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma:Significant toxicity with no clinical efficacy","volume":"106","author":"Wyman","year":"2006","journal-title":"Cancer"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"Heinrich","year":"2006","journal-title":"J Clin Oncol"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1634\/theoncologist.2015-0161","article-title":"Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration:A multicenter trial of Korean Cancer Study Group (UN10-06)","volume":"20","author":"Lee","year":"2015","journal-title":"Oncologist"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/JTO.0b013e3182a7d22e","article-title":"Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing","volume":"9","author":"Hagemann","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"(Suppl 1)","key":"R28-20241021","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.leukres.2003.10.004","article-title":"Targeting c-Kit mutations:Basic science to novel therapies","volume":"28","author":"Sattler","year":"2004","journal-title":"Leuk Res"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.molcel.2018.08.040","article-title":"The Proto-oncogene c-Kit inhibits tumor growth by behaving as a dependence receptor","volume":"72","author":"Wang","year":"2018","journal-title":"Mol Cell"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies:Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2698_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:08Z","timestamp":1787067548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2698_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2698_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"2022-12-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}